Clinical Trial: IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07122687) titled 'IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer' on June 24.

Brief Summary: This study is a randomized, open-label Phase 2 study to compare the efficacy and safety of IBI363 Combined with Chemotherapy or Pembrolizumab Combined with Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer.

Study Start Date: Aug. 29

Study Type: INTERVENTIONAL

Condition: Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Intervention: DRUG: Pemetrexed

500 mg/m2 D1 IV Q3...